Genelux (GNLX) Net Cash Flow (2022 - 2026)
Genelux's (GNLX) quarterly Net Cash Flow came in at $3.9 million in Q1 2026, down 48.44% year-on-year from $7.6 million in Q1 2025, and up 514.66% quarter-over-quarter from $641000.0 in Q4 2025.
Genelux (GNLX) Net Cash Flow (2022 - 2026) Analysis & Trends
Genelux's Net Cash Flow history runs 5 years deep, the most recent figure standing at $3.9 million for Q1 2026.
- On a quarterly basis, Net Cash Flow fell 48.44% year-over-year to $3.9 million in Q1 2026; TTM through Mar 2026 was -$6.9 million, a 157.09% decrease from a year earlier, with the FY2025 full-year figure at -$3.2 million, down 278.9% from the prior year.
- Net Cash Flow climbed to $3.9 million in Q1 2026 per GNLX's latest filing, from $641000.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $16.8 million in Q2 2023 and bottomed at -$20.5 million in Q4 2023.
- The 5-year median for Net Cash Flow is $2.5 million (2024), against an average of $705533.3.
- Biggest YoY gain for Net Cash Flow was 270.93% in 2023; the steepest drop was 2001.85% in 2023.
- Year by year, Net Cash Flow stood at -$973000.0 in 2022, then slumped by 2001.85% to -$20.5 million in 2023, then surged by 112.04% to $2.5 million in 2024, then tumbled by 73.97% to $641000.0 in 2025, then jumped by 514.66% to $3.9 million in 2026.
- Per Business Quant, the three latest GNLX Net Cash Flow figures stand at $3.9 million (Q1 2026), $641000.0 (Q4 2025), and -$1.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -2.44 Mn |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn | 224.46 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Genelux | 128.92 Mn | 128.92 Mn | - | 3.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.94 Mn |
| Mar 31, 2026 | 3.94 Mn |
| Dec 31, 2025 | 641,000.00 |
| Dec 31, 2025 | 641,000.00 |
| Sep 30, 2025 | -1.85 Mn |
| Sep 30, 2025 | -1.85 Mn |
| Jun 30, 2025 | -9.67 Mn |
| Jun 30, 2025 | -9.67 Mn |
| Mar 31, 2025 | 7.64 Mn |
| Mar 31, 2025 | 7.64 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Sep 30, 2024 | -1.76 Mn |
| Sep 30, 2024 | -1.76 Mn |
| Jun 30, 2024 | 3.80 Mn |
| Jun 30, 2024 | 3.80 Mn |
| Mar 31, 2024 | -5.36 Mn |
| Mar 31, 2024 | -5.36 Mn |
| Dec 31, 2023 | -20.45 Mn |
| Dec 31, 2023 | -20.45 Mn |